Emactuzumab
- Generic Name
- Emactuzumab
- Drug Type
- Biotech
- CAS Number
- 1448221-67-7
- Unique Ingredient Identifier
- 6FY6EI1X8R
- Background
Emactuzumab is under investigation in clinical trial NCT01494688 (A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors).
Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- SynOx Therapeutics Limited
- Target Recruit Count
- 128
- Registration Number
- NCT05417789
- Locations
- 🇺🇸
NextGen Oncology, Beverly Hills, California, United States
🇺🇸University of Kansas Cancer Center (Overland Park) - USOR, Overland Park, Kansas, United States
🇺🇸Duke Cancer Center, Durham, North Carolina, United States
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1000
- Registration Number
- NCT03768063
- Locations
- 🇩🇪
Universitaets-Hautklinik Tuebingen, Tübingen, Germany
🇩🇪Universitaettsklinikum Tübingen, Tübingen, Germany
🇩🇪Universitätsklinik Tübingen, Tübingen, Germany
A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT03369964
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
- First Posted Date
- 2016-05-04
- Last Posted Date
- 2018-05-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 38
- Registration Number
- NCT02760797
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸University Pennsylvania Hospital, Philadelphia, Pennsylvania, United States
🇫🇷Institut Gustave Roussy; Sitep, VILLEJUIF Cedex, France
A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2020-08-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 221
- Registration Number
- NCT02323191
- Locations
- 🇺🇸
Dana Farber - Harvard, Boston, Massachusetts, United States
🇺🇸Memorial Sloan-Kettering Cancer Center Breast & Imaging Center, New York, New York, United States
🇪🇸Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain
A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2018-03-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 217
- Registration Number
- NCT01494688
- Locations
- 🇫🇷
Centre Leon Berard; Departement Oncologie Medicale, Lyon, France
🇺🇸Univ of Pennsylvania Med Ctr, Philadelphia, Pennsylvania, United States
🇫🇷Institut Curie; Oncologie Medicale, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.